Neuropharm reins in R&D expenses as fluoxetine progresses in autism
This article was originally published in Scrip
Executive Summary
Neuropharm is progressing in its attempts to bring its lead product NPL-2008, a low-dose form of fluoxetine, to market for the treatment of autism, and has posted cash and cash equivalents of £12.7 million in its full-year financial results.